Descrizione del progetto
Un test pratico e accessibile per la malattia da fattore Rh
Nei paesi sviluppati, la malattia da fattore Rh (anche nota come malattia emolitica del feto e del neonato) si considera debellata. Altrettanto non avviene nei paesi in via di sviluppo, dove continua a causare gravi problemi di salute e persino decessi. Nonostante i decessi possano essere evitati attraverso lo screening del tipo di fattore RhD, la maggior parte delle donne in gravidanza non viene sottoposta al test. Il progetto ABOPEN, finanziato dall’UE, presenta un test del gruppo sanguigno intuitivo, affidabile, accessibile e per uso personale, che funziona in modo analogo ai test di gravidanza, con l’identificazione del tipo di fattore RhD in soli 60 secondi attraverso un processo in un’unica fase. Il dispositivo può essere conservato per più di 24 mesi a temperatura ambiente, non richiede l’intervento di personale qualificato e può essere utilizzato per la determinazione dei gruppi sanguigni in situazioni di emergenza.
Obiettivo
Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type.
At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of EldonCards (a pioneering off-the-lab dry format grouping test) in more than 44 countries and has built a well-established worldwide network of customers and distributors. We are part of the influential International Federation of Gynecology and Obstretics (FIGO) and founding member of CURhE, an international initiative to stop HDNF. Now, we are moving one step further from EldonCards overcoming its limitations to erase HDNF from developing countries. To do so, we have created ABOPEN, a user-friendly off-the-lab grouping test that can be stored for up to 24 months at 37C and works similarly to pregnancy tests, identifying the RhD factor type in just 1 minute and a single-step procedure. ABOPEN can be performed outside a laboratory setting (does not need electricity) by non-trained personnel, while keeping its affordability (it costs just €4), precision and accuracy. ABOPEN has also a sizeable market in developed countries, as an instant and easy to use device to find out about blood grouping for urgent transfusions (accidents, hospitals, military) or just personal information.
By end of 2025, we expect to generate €8 million in turnover (ROI of 2.2) while creating 7 new jobs for the company.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
2820 GENTOFTE
Danimarca
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.